Physician profile
James E Lantz
NPI 1881667822
$10,181.43
in general payments reported to CMS, 2019-2025
42 companies · $21.70 in 2025
The $21.70 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,048 · 2020: $1,695 · 2021: $1,933 · 2022: $2,044 · 2023: $2,156 · 2024: $283 · 2025: $21.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,460.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,460.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,535.69 | 2019-2023 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $1,452.11 | 2019-2023 | Farxiga, Breztri |
| Amgen INC. | $927.55 | 2019-2023 | Otezla, Repatha |
| Amarin Pharma, INC. | $798.33 | 2019-2022 | |
| Lilly USA, LLC | $697.04 | 2019-2023 | Mounjaro, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $539.94 | 2021-2023 | |
| Abbvie INC. | $518.86 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $394.59 | 2019-2023 | Jardiance |
| Sanofi-Aventis U.S. LLC | $373.66 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $332.05 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Pfizer INC. | $316.04 | 2019-2023 | |
| Abiomed | $265.58 | 2024 | Impella |
| Astellas Pharma US INC | $237.34 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $215.67 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $210.79 | 2019-2023 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Lantz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.